Sa083 SYMPTOMATIC IMPROVEMENT WITH VEDOLIZUMAB THERAPY FOR CROHN'S DISEASE STRATIFIED BY DISEASE ACTIVITY AND PRIOR TUMOR NECROSIS FACTOR ANTAGONIST FAILURE: POST HOC ANALYSES FROM THE GEMINI 2 TRIAL

Autor:	Geert R. D'Haens, Sharif M. Uddin, Ninfa Candela, Theresa C. Peterson, Marla Dubinsky, Karen Lasch, Jean-Frederic Colombel
Rok vydání:	2021
Předmět:	Crohn's disease medicine.medical_specialty Hepatology Post hoc business.industry Gastroenterology Antagonist medicine.disease Vedolizumab Disease activity Internal medicine Medicine Tumor necrosis factor alpha business medicine.drug
Zdroj:	Gastroenterology. 160:S-414
ISSN:	0016-5085
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f5e91c638cda377e26118dcfa5518059 https://doi.org/10.1016/s0016-5085(21)01696-6 Zobrazit plný text záznamu